Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD
|
|
- Jeremy McCormick
- 5 years ago
- Views:
Transcription
1 1 The National Academies of Sciences, Engineering and Medicine Regulatory Strategies of address prescription opioidrelated harms 4 th of November, 2016 Washington DC Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women Hendrée E. Jones, PhD Executive Director, Horizons Program Professor, Department of Obstetrics and Gynecology School of Medicine, University of North Carolina at Chapel Hill
2 2 Outline 1) Review the historical and current context of drug labeling for pregnancy and lactation 2) Highlight challenges and opportunities with current safety labeling of opioid agonist medications to treat opioid use disorder during pregnancy and lactation
3 3 History of Drug Labels with Pregnancy Information 1960 s Thalidomide FDA said all pregnant women on methadone should undergo a 21-day detoxification- it was later reversed FDA regulations include pregnancy information when labeling drugs FDA convenes a hearing to review A-D and X pregnancy categories Letter to FDA by National Association of Attorneys General about NAS; Opioid pain medication labeling - NOWS precautions added FDA Pregnancy and Lactation Labeling Rule in effect FDA requires methadone and buprenorphine safety labeling to include the risk of neonatal opioid withdrawal syndrome (NOWS) Zuspan et al. Am J Obstet Gynecol. 1975;122:43-46; Greene Seminars in Perinatology 2015: ; U.S. Food and Drug Administration (FDA). Neonatal opioid withdrawal syndrome and medication-assisted treatment with methadone and buprenorphine. Updated May 26, Accessed October 24, 2016.
4 4 Defining NAS (also known as NOWS) Neonatal Abstinence Syndrome (NAS) or Neonatal Opioid Withdrawal (NOWS) often results when a pregnant woman uses opioids (e.g., heroin, oxycodone) during pregnancy. Defined by alterations in the: Central nervous system high-pitched crying, irritability exaggerated reflexes, tremors and tight muscles sleep disturbances Autonomic nervous system sweating, fever, yawning, and sneezing Gastrointestinal distress poor feeding, vomiting and loose stools Signs of respiratory distress nasal stuffiness and rapid breathing There are risks and benefits with using NOWS over NAS There are multiple factors that drive NAS/NOWS severity NAS and treatment are not known to have long-term effects; interactions between the caregiver and child can impact resiliency/risk with potential long-term effects in some cases. Finnegan et al., Addict Dis, 1975; Desmond & Wilson, Addict Dis, 1975; Jones & Fielder, Preventive Medicine, 2015.
5 5 Previous Opioid Agonist Labels: Pregnancy Information ROXANE LABORATORIES, INC. Columbus, OH DOLOPHINE HYDROCHLORIDE CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg Rx Only Pharmacokinetics in Special Populations Pregnancy The disposition of oral methadone has been studied in approximately 30 pregnant patients in 2nd and 3rd trimesters. Elimination of methadone was significantly changed in pregnancy. Total body clearance of methadone was increased in pregnant patients compared to the same patients postpartum or to non-pregnant opioid-dependent women. The terminal half-life of methadone is decreased during 2nd and 3rd trimesters. The decrease in plasma half-life and increased clearance of methadone resulting in lower methadone trough levels during pregnancy can lead to withdrawal symptoms in some pregnant patients. The dosage may need to be increased or the dosing interval decreased in pregnant patients receiving methadone. (See PRECAUTIONS: Pregnancy, Labor and Delivery, and DOSAGE AND ADMINISTRATION.) Infants born to mothers physically dependent on opioids may also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms (see PRECAUTIONS; Pregnancy, Labor and Delivery).
6 6 History of Drug Labels with Pregnancy Information 2013 Letter to FDA by National Association of Attorneys General about NAS; Opioid pain medication labeling - NOWS precautions added
7 7 Stakeholder Concern: Potential Negative Impact of Labeling Changes June 2013 letter from American Society of Addiction Medicine September 2013 letter from American College of Obstetrics and Gynecology October 2013 Citizen Petitions from National Advocates for Pregnant Women Could reduce number of pregnant women with opioid use disorder who are recommended to or maintained on opioid agonist treatment Discontinuation of treatment likely to result in relapse to nonmedical use of opioids, which will increase risk to pregnant women and their babies Labeling could be used to justify punitive and counterproductive child welfare interventions Could lead pregnant women with opioid use disorder to avoid seeking treatment and/or prenatal care
8 8 Current Opioid Agonist Labels: Pregnancy Information Current NOWS Labeling in ER/LA Opioid Analgesics (approved 4/16/14) Boxed Warning: Prolonged use of TRADENAME during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. Warnings and Precautions 5.3 Neonatal Opioid Withdrawal Syndrome: Prolonged use of TRADENAME during pregnancy can result in withdrawal signs in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. 8.1 Pregnancy: Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Observe newborns for symptoms
9 9 History of Drug Labels with Pregnancy Information 1960 s Thalidomide FDA said all pregnant women on methadone should undergo a 21-day detoxification- it was later reversed FDA regulations include pregnancy information when labeling drugs FDA convenes a hearing to review A-D pregnancy categories Letter to FDA by National Association of Attorneys General about NAS; Opioid pain medication labeling - NOWS precautions added FDA Pregnancy and Lactation Labeling Rule in effect FDA requires methadone and buprenorphine safety labeling to include the risk of neonatal opioid withdrawal syndrome (NOWS) Zuspan et al. Am J Obstet Gynecol. 1975;122:43-46; Greene Seminars in Perinatology 2015: ; U.S. Food and Drug Administration (FDA). Neonatal opioid withdrawal syndrome and medication-assisted treatment with methadone and buprenorphine. Updated May 26, Accessed October 24, 2016.
10 10 Response to Current Opioid Agonist Labels: Pregnancy Practice Advisory: FDA Boxed Warning on Immediate- Release Opioid Medications and All Prescription Opioids March 24, 2016 On March 22nd, 2016, the U. S. Food and Drug Administration (FDA) announced required, class-wide safety labeling changes for immediate-release opioid pain medications. As part of these changes, the FDA is now requiring a new boxed warning ( black box warning) about the serious risks of misuse, abuse, addiction, overdose, and death on all prescription opioids. The boxed warning will also include a precaution that chronic maternal opioid use during pregnancy can result in neonatal abstinence syndrome (NAS, referred to in the FDA warning as neonatal opioid withdrawal syndrome or NOWS ), described as a condition that may be life-threatening if not recognized and treated using protocols developed by neonatology experts. The FDA has included messaging that treatment should not be abruptly stopped in a physically dependent patient, although this is not specifically stated in regards to a pregnant patient, nor is this messaging in the boxed warning.
11 11 Current Opioid Agonist Labels: Unintended Consequences NAS/NOWS The FDA warning emphasizes the potential greater risk if NAS is unexpected or unrecognized - no data that support the distinction between recognized and unrecognized nor opioid use and subsequent neonatal death. Concerns related to unexpected or unrecognized NAS are related to the process of identifying women using chronic opioids and are not a direct result of the medication or drug itself. Opioid use clearly contributes to the clinical spectrum of NAS, the identification of women who use opioids chronically is a separate issue. Opposite to the intended effect of FDA s new labeling rules, this identification may become more challenging with the universal implementation of a boxed warning on opioids.
12 12 Current Opioid Agonist Labels: Unintended Consequences Impact on Care of Pregnant Women Patients may be denied access to medically indicated opioid prescriptions (either for pain management or opioid-assisted therapy), potentially resulting in an abrupt discontinuation of opioids. Boxed warning was specifically assigned to immediate-release formulations. Immediate-release formulations may be abused, but there are clearly appropriate indications for the use of opioids May negatively impact the appropriate use of opioids in acute pain management for pregnant women, further limiting appropriate pain management options.
13 13 Current Opioid Agonist Labels: Unintended Consequences Impact on Mothers and Children Boxed warning may be used to show mother harmed child prenatally May be used as evidence to support termination of parental rights
14 14 New Rule: Drug Labels with Pregnancy Information New label has four sub-headings Pregnancy exposure registry Risk Summary Clinical Considerations Data Note: Pregnancy A-D categories has been removed Greene Seminars in Perinatology 2015:
15 15 Current Concern: Opioid Use during Pregnancy Examined whether maternal opioid treatment between 1 month before pregnancy and the first trimester was associated with birth with at least 200 case infants or at least 4 exposed case infants using data from National Birth Defects Prevention Study for the period1997 through Therapeutic opioid use was reported by 2.6% of 17,449 case mothers and 2.0% of 6,701 control mothers Opioid treatment was statistically significantly associated with conoventricular septal defects atrioventricular septal defects hypoplastic left heart syndrome spina bifida gastroschisis Modest absolute increase in risk above the baseline birth defects risk. For example, the estimated birth prevalence of hypoplastic left heart syndrome in the United States is 2.4/10,000 live births Findings suggest a potentially 2.4-fold increased risk for a hypoplastic left heart syndrome-affected pregnancy in a woman taking opioid analgesics periconceptionally Would suggest up to a 5.8 in 10,000 (0.06%) chance of that woman having an infant with hypoplastic left heart syndrome Broussard et al., Am J Obstet Gynecol. 2011
16 16 Current Concern: Opioid Use during Pregnancy Three concerns severely limit the future research and clinical usefulness of these findings: 1. There is an important difference between relative risk and absolute risk 2. Drug use data are collected retrospectively between 6 weeks and 2 years post delivery 3. Measuring tobacco use as periconceptional smoking status (no-smoking from 1 month before to 1 month postconception, smoking at least once in the same period) equates mothers smoking 1 cigarette once to mothers smoking 2 packs daily. These 2 measurement lapses seriously threaten the study's statistical conclusion validity. 3. Respondents (66%) reported common prescription opioid use reasons were surgical procedures (41%), infections (34%), chronic diseases (20%), and injuries (18%). The extent that these issues are independently related to the birth defects described is unknown. Also unknown is whether or not the cases and controls differed in their respective prevalence of these events. These are stressful events, and stress can influence fetal and neonatal outcomes Omitting the measurement and statistical control of stressful events potentially biases the results The potential relationship between birth defects and other medications (e.g., acetaminophen) that are present in opioid analgesic medications was not addressed Jones et al., Am J Obstet Gynecol
17 17 Summary Boxed warning overemphasizes the risks of NAS without appropriately acknowledging that there are even greater risks associated with abrupt cessation of opioids in the population most effected Labels need to be more easily updated and provide userfriendly data summaries of emerging risk and benefit data Research needs to answer questions about unintended consequences of boxed warnings and the language used to convey warnings
18 18 Acknowledgements Contact Michael Greene MD Hendrée E Jones, PhD Executive Director, UNC Horizons Professor, Department of Obstetrics and Gynecology School of Medicine University of North Carolina at Chapel Hill 127 Kingston Drive Chapel Hill, NC USA Hendree_Jones@med.unc.edu Direct Line: Main Office: Fax:
Treating Women for Opioid Use Disorder during Pregnancy: Methadone and Buprenorphine as a Part of a Complete Care Approach
Treating Women for Opioid Use Disorder during Pregnancy: Methadone and Buprenorphine as a Part of a Complete Care Approach Hendrée E. Jones, PhD Executive Director, UNC Horizons Professor, Department of
More informationOpioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard
Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among
More informationTreating Women for Substance Use Disorders and Their Children: Evidence-based Care
Treating Women for Substance Use Disorders and Their Children: Evidence-based Care Hendrée E. Jones, PhD Executive Director, UNC Horizons Professor, Department of Obstetrics and Gynecology School of Medicine,
More informationOpioid Use Disorder in Pregnancy. Neonatal Abstinence Syndrome
Opioid Use Disorder in Pregnancy Neonatal Abstinence Syndrome Opioid Use Disorder and Pregnancy Cont. 4.6 million women (or 3.8 percent) ages 18 and older misused prescription drugs in 2013. One-third
More informationObjectives. Care of the Neonate with Prenatal Opioid Exposure. What is Neonatal Abstinence Syndrome (NAS)? Increasing Incidence of NAS 8/27/2016
Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute
More informationPresented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay
Presented by DCF SunCoast Region: Kyle Teague, Melissa Worthen, Christina Cuoco, Nina Romeu, Dekesha Seay Overview/Learning Objectives What is Addiction Medication Assisted Treatment Discuss facts about
More informationCare of the Neonate with Prenatal Opioid Exposure. Objectives. What is Neonatal Abstinence Syndrome (NAS)/ Neonatal Opiate Withdrawal Syndrome?
Care of the Neonate with Prenatal Opioid Exposure Heather Pratt Chavez, MD Ann Winegardner, MD Objectives Review the latest population data on neonates with prenatal opioid exposure Describe the acute
More informationThe Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome
Neonatal Nursing Education Brief: The Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome https://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/
More informationState of the Science on Pregnant and Parenting Women with Substance Use Disorder
State of the Science on Pregnant and Parenting Women with Substance Use Disorder Hendrée E. Jones, PhD Executive Director, UNC Horizons Professor, Department of Obstetrics and Gynecology School of Medicine
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More informationOpioid Use Disorders and Pregnancy. Marcela Smid, MD Maternal-Fetal Medicine
Opioid Use Disorders and Pregnancy Marcela Smid, MD Maternal-Fetal Medicine UNIVERSITY OF UTAH HEALTH, 2017 OBJECTIVES Definitions Epidemiology Pharmacology Effects on pregnancy Screening Treatment CARE
More informationAddiction and Pregnancy. Jim Walsh, MD Medical Director Addiction Recovery Service Swedish Medical Center WSADCP October 2018
Jim Walsh, MD Medical Director Addiction Recovery Service Swedish Medical Center WSADCP October 2018 Fear Shame Commitment Barriers Opportunities Fear Thalidomide induced phocomelia 1957 Fear Fetal Alcohol
More informationConsequences and Treatment of Opioid Abuse During Pregnancy. Katie Ellis, PharmD March 12, 2018
Consequences and Treatment of Opioid Abuse During Pregnancy Katie Ellis, PharmD March 12, 2018 Disclosure I have nothing to disclose. Objectives At the completion of this activity, the pharmacist will
More informationNeonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention
Neonatal Abstinence Syndrome Epidemiology, diagnosis, management and prevention Cynthia Thomas, DO,MPH Northeast Regional Health Office Tennessee Department of Health Disclosure Statement of Financial
More informationSUBSTANCE EXPOSED INFANTS PRESENTED BY ECOLE J. BARROW-BROOKS M.ED & DARLENE D. OWENS MBA, LBSW, CADC, ADS
SUBSTANCE EXPOSED INFANTS PRESENTED BY ECOLE J. BARROW-BROOKS M.ED & DARLENE D. OWENS MBA, LBSW, CADC, ADS 1 SUBSTANCE-EXPOSED INFANTS Refers to infants exposed to alcohol and or other substances ingested
More informationEmergent Issues Affecting Early Intervention/ Early Childhood. Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC
Emergent Issues Affecting Early Intervention/ Early Childhood Workforce Development for Inclusion in Early Childhood November 4, 2017 Washington, DC Conversation Points Changing Demographics Emergent Trends
More informationLori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center
Lori A. Shook, MD Division of Neonatology Kentucky Children s Hospital University of Kentucky Medical Center NSDUH, 2012 National Survey on Drug Use and Health: 2012 Substance abuse: Public Health Problem
More informationNAS / NOWS: Description. Disclosures: I will discuss off-label uses of medications I have no financial disclosures. Objectives
Opioid-exposed Newborns and Their Families the Vermont Approach Anne Johnston, MD Neonatal Perinatal Medicine Associate Professor of Pediatrics University of Vermont Disclosures: I will discuss off-label
More informationNeonatal Abstinence Syndrome:
Neonatal Abstinence Syndrome: Rethinking Our Approach Matthew Grossman, M.D. Assistant Professor of Pediatrics Yale School of Medicine Quality and Safety Officer Yale-New Haven Children s Hospital Patrick,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine
More informationAdvancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance
Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical
More information9/19/13. Postpartum Counseling for Women in MAT. Katie Clark MSPH, CSAC. A little about Katie. Definitions. MAT: Medication-Assisted Treatment
Postpartum Counseling for Women in MAT Katie Clark MSPH, CSAC A little about Katie SUD and PH crossroads BA Health Arts and Sciences Goddard College MSPH MCH UNC Project Lazarus, Yale, CHER Solutions LLC
More informationMAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids
MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE
More informationOpioid Addiction and Dependence in Pregnancy
Opioid Addiction and Dependence in Pregnancy Amy Langenfeld MS, APRN, CNM, PHN, SANE-A Some of the things we will cover today... Discuss opioid addiction trends in Minnesota. Discuss the identification
More informationOpiate Use in Reproductive Age Females
Opiate Use in Reproductive Age Females February 15, 2017 2:00 pm-3:00 pm ET In order to hear the presentation please call +1 (562) 247-8422, access code 579-542-512 All Participant Phone Lines are Muted
More informationScience = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse
Science = Solutions For Substance Use Disorders and Infant Outcomes Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions Increased Opioid Mortality: Greater
More informationNeonatal Drug Withdrawal
History Neonatal Drug Withdrawal Katherine Wang, MD, FAAP Avera McKennan Children s Hospital NICU Morphine has been used for pain for many years Congenital morphinism was not recognized as an entity until
More informationPublic Policy Statement on Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids
Public Policy Statement on Substance Use, Misuse, and Use Disorders During and Following Pregnancy, with an Emphasis on Opioids Background The American Society of Addiction Medicine (ASAM) is deeply committed
More informationPROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing MODULE 3
PROJECT DOVE Improving Maternal and Neonatal Health Through Safer Opioid Prescribing MODULE 3 Partners Support Bureau of Justice Assistance, Department of Justice Grant # PM-BX-Koo4 Treatment Plan MODULE
More information2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society
Pregnant Women Who Use Drugs: Stigma, Science and Society Mishka Terplan MD MPH FACOG FASAM Professor Departments Obstetrics and Gynecology and Psychiatry Associate Director Addiction Medicine Virginia
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationThe Opioid-Exposed Woman
The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus
More information8/24/2015 ADDICTION AND PREGNANCY. Fear ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY ADDICTION & PREGNANCY
ADDICTION AND PREGNANCY L y n é e B r o w n, M A, C D P & D o n n a L i v i n g s t o n, R N A D A P T E D F R O M J i m W a l s h, M D Objectives: Recognize common fears and myths associated with substance
More informationTobacco Cessation for Women of Reproductive Age. Erin McClain, MA, MPH
Tobacco Cessation for Women of Reproductive Age Erin McClain, MA, MPH Tobacco Use During Pregnancy in NC 2 1 in 10 babies in NC are born to women reporting tobacco use during pregnancy In some counties
More informationNeonatal abstinence syndrome
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Neonatal Abstinence Syndrome. These podcasts are designed to give medical students an overview of key topics in pediatrics.
More informationKRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH
KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH IF THESE MOMS REALLY CARED ABOUT THEIR BABIES, THEY WOULD JUST QUIT Those who can quit, often do Addiction
More informationMedication for the Treatment of Addiction (MAT)
Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication
More informationMedication-Assisted Treatment & Pregnancy. Dave Kneessy, MS, MAC, CAP, LMHC Regional Director Central Florida Treatment Centers
Medication-Assisted Treatment & Pregnancy Dave Kneessy, MS, MAC, CAP, LMHC Regional Director Central Florida Treatment Centers Addiction/ Substance Use Disorder Addiction is a Biopsychosocial Disease Has
More informationPregnancy, Opioid Addiction, and Care Issues in Virginia
Pregnancy, Opioid Addiction, and Care Issues in Virginia Mishka Terplan MD MPH FACOG FASAM Professor Departments Obstetrics and Gynecology and Psychiatry Associate Director Addiction Medicine Virginia
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More information4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING
Opioid Use Disorder in Pregnancy 2017 Recommendations from ACOG and The Pew Charitable Trust KATHY D. HARTKE, MD, LEGISLATIVE CO-CHAIR AND IMMEDIATE PAST CHAIR, WISCONSIN SECTION OF THE AMERICAN COLLEGE
More informationMEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only
MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency
More information... Health. Department of. Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN. Overview and Regional Snapshot
Department of... Health Prenatal Drug Exposure and Neonatal Abstinence Syndrome in Northeast TN Overview and Regional Snapshot Cynthia C. Thomas, DO, MPH, Assistant Health Officer, Northeast Regional Health
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More information2/24/2014. Bridging the Gap Between Behavioral Health and Pregnancy. My Background and Interest in the Topic... Plan for Today
Bridging the Gap Between Behavioral Health and Pregnancy Amelia Mahan MSW, LCSW Behavioral Health Program Manager amahan@n3cn.org; (919) 926-3918 My Background and Interest in the Topic... Stumbled into
More informationMarijuana in the Obstetric Population
Marijuana in the Obstetric Population Brittany MacGregor PGY 1 on behalf of Sophia Lenson PGY 3, Queens OB/Gyn Objectives 1. Review the status of legalization of cannabis products in Canada and the potential
More informationOpioid Use Disorder. in Pregnancy: Care and Context of Mother and Newborn
Opioid Use Disorder in Pregnancy: Care and Context of Mother and Newborn PRESENTED BY: Mishka Terplan MD MPH FACOG FASAM Kelley Saia MD FACOG DABAM Elizabeth Krans MD MSc FACOG September, 22 2016 Medicaid
More informationEI Leadership April 24, 2018
Early Childhood Community Partnerships to Support Families Struggling with SUD EI Leadership April 24, 2018 Setting the Stage The issue of young children impacted by substance use disorders in families
More informationUnderstanding Prenatal Drug Exposure
Understanding Prenatal Drug Exposure Prenatal Drug Exposure A mother s drug use hurts her unborn baby. Slide 2 Drug Categories Part 1 Prescription drugs: Prescribed by a doctor and used under a health
More informationObjectives. Common Drugs leading to NAS. Differential Diagnosis. Clinical Features of NAS. Assessing Neonatal Abstinence in the Newborn Nursery
Objectives Assessing Neonatal Abstinence in the Newborn Nursery WAPC Annual Meeting 2012 Elizabeth Goetz MD Mary Rolloff PhD, RN, CNE At the conclusion of this session participants will be able to: Understand
More informationOpioid use in pregnancy and Neonatal Abstinence Syndrome
Opioid use in pregnancy and Neonatal Abstinence Syndrome Morissa Ladinsky, MD Assoc. Professor of Pediatrics Division of General Pediatrics and Adolescent Medicine UAB Objectives 1. Understand the magnitude,
More informationOpioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center
Opioid Use Disorder- Pregnancy Principles and Myths Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center History of NAS/NOWS Prior to 1875 infants not thought to be affected Congenital Morphinism
More informationIN-PATIENT PEDIATRIC REHABILITATION
IN-PATIENT PEDIATRIC REHABILITATION Neonatal Abstinence Syndrome Program Carissa H. Snelling, MS, OTR/L, BCP Erika Herzer, PT, DPT, PCS, CBIS April 2017 CHARACTERISTICS OF NAS Drug(s) Opioids Cocaine Benzodiazepines
More informationINTRODUCTION. Baltimore, Maryland 6 School of Medicine West Virginia University, Morgantown, West Virginia
The American Journal on Addictions, 27: 92 96, 2018 Copyright 2018 American Academy of Addiction Psychiatry ISSN: 1055-0496 print / 1521-0391 online DOI: 10.1111/ajad.12687 Brief Report: Treating Women
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationNeonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)
Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit
More informationEffects of Prenatal Illicit Drug. Use on Infant and Child
Effects of Prenatal Illicit Drug Use on Infant and Child Development Andrew Hsi, MD, MPH Larry Leeman, MD, MPH Family Medicine MCH Grand Rounds 6 July 2011 Objectives for Presentation At the end of this
More informationMEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP
MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP IMPORTANT: Keep oxycodone hydrochloride oral solution in a safe place away from children. Accidental use by a child is
More informationPrescription Opioids
What are prescription opioids? Prescription Opioids Opioids are a class of drugs naturally found in the opium poppy plant. Some prescription opioids are made from the plant directly, and others are made
More informationOutcomes of Infants with Neonatal Abstinence Syndrome
Outcomes of Infants with Neonatal Abstinence Syndrome Caroline O. Chua, MD, FAAP Medical Director, Division of Neonatology Director, Neonatal Follow Up Clinic Nemours Children s Hospital Orlando, Florida
More informationNeonatal Abstinence Syndrome
5 Neonatal Abstinence Syndrome Amy P. Holmes, PharmD Introduction Neonatal abstinence syndrome (NAS) is recognized as the effect of intrauterine exposure to substances that can cause physical dependence.
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationRelationships Relationships
PRENATAL OPIATE EXPOSURE IMPACT ON EARLY CHILDHOOD LEARNING AND BEHAVIOR Ira J. Chasnoff, MD NTI Upstream www.ntiupstream.com Children grow and develop in the context of Attachment: Basic Concept Attachment:
More informationDilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such as that due to:
DrugFAQs Dilaudid Generic name: Hydromorphone hydrochloride Brand names: Dilaudid Why is Dilaudid prescribed? Dilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such
More informationSafe Babies Foster Parent Training Program
Safe Babies Foster Parent Training Program Module 1: Introduction to the Safe Babies Program 1 Begin the process of group participation Learning outcomes Understand the purpose and origins of the Safe
More informationThe Impact of Addiction on Infant Mortality
Congressional Addiction, Treatment and Recovery Caucus and the Bipartisan Task Force to Combat the Heroin Epidemic Hosts: The Impact of Addiction on Infant Mortality Arthur R. James MD, FACOG Ohio State
More informationPERINATAL TOBACCO USE
PERINATAL TOBACCO USE Child Fatality Task Force Meeting December 7, 2015 Erin McClain, MA, MPH You Quit, Two Quit, UNC Center for Maternal & Infant Health Percentage Women & Tobacco Use in NC 2 50 45 40
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationPOWER TO HELP REVERSE AN OPIOID OVERDOSE
POWER TO HELP REVERSE AN OPIOID OVERDOSE FDA APPROVED Concentrated 4 mg dose Needle-free; no assembly required Designed for ease-of-use in the community setting Requires no specialized training* Not a
More informationSUBSTANCE EXPOSED NEWBORNS
Substance Exposed Newborns 1 SUBSTANCE EXPOSED NEWBORNS STATE OF OKLAHOMA 2012 2 Substance Exposed Newborns The mission of the Oklahoma Department of Human Services is to help individuals and families
More informationFacts About BELBUCA (buprenorphine) Buccal Film
Facts About BELBUCA (buprenorphine) Buccal Film Indication BELBUCA is a recent FDA-approved medication for the treatment of chronic pain severe enough to require daily, around-the-clock, long-term opioid
More informationClinical Management of Neonatal Abstinence Syndrome. Tricia L. Romesberg, DNP, MSN, ARNP, CNNP
Clinical Management of Neonatal Abstinence Syndrome Tricia L. Romesberg, DNP, MSN, ARNP, CNNP Timeline Incidence of NAS Healthcare Cost and Utilization Project (HCUP), 1999-2013 State Inpatient Databases
More informationBuprenorphine & Controlled Substance Treatment Agreement
Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a
More informationObjectives. Nothing to Disclose No Conflicts of Interest
April 22, 2014 PCSS-MAT Webinar Lori Devlin, DO, MHA Assistant Professor- Department of Pediatrics University of Louisville School of Medicine Nothing to Disclose No Conflicts of Interest Objectives Define
More informationAnesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a
Appendix 1. Literature Search Databases Years Search Terms Pubmed 01/1966 1. Analgesics, Opioid a / or Opioid-related Disorders a / PsycINFO EMBASE Cochrane 09/2016 or Heroin a / or Heroin Dependence a
More informationSupersedes Date None and Management Guidelines. Originating Dept. NICU Document Owner Dir., NICU Document applies to: NCH Required Not Required
Effective Date 12/13/16 Neonatal Abstinence Syndrome (NAS) Date Approved 12/13/16 Guideline Pharmacologic Protocol Supersedes Date None and Management Guidelines Originating Dept. NICU Document Owner Dir.,
More informationPERINATAL TOBACCO USE
PERINATAL TOBACCO USE Child Fatality Task Force Perinatal Health Committee Meeting November 4, 2015 Erin McClain, MA, MPH You Quit, Two Quit, UNC Center for Maternal & Infant Health Percentage Women &
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More informationThe safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.
These products are indicated in the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More information1/26/2018 PREVENTING THE RETRAUMITIZATION OF CHILDREN FROM ADDICTED FAMILIES THE PROBLEM RISK FACTORS FOR ENDANGERMENT
PREVENTING THE RETRAUMITIZATION OF CHILDREN FROM ADDICTED FAMILIES Susan Kilman LCSW, AADC THE PROBLEM ABOUT 1 IN 8 (8.7 MILLION) AGED 17 OR YOUNGER LIVE IN HOUSEHOLDS WITH AT LEAST ONE PARENT WHO HAD
More informationMethadone hydrochloride IntensolTM (oral concentrate USP), for oral use, CII Initial U.S. Approval: 1947
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Methadone hydrochloride IntensolTM (oral concentrate USP) safely and effectively. See full prescribing
More informationWales Neonatal Network Guideline
Guideline on the Management of Neonatal Abstinence Syndrome Introduction Neonatal Abstinence Syndrome (NAS) is a constellation of symptoms and signs occurring in a baby as a result of withdrawal from physically
More informationWhat is the most important information I should know about Morphine Sulfate Oral Solution?
Medication Guide MORPHINE SULFATE (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
More informationDrugs cross the placenta producing a new set of pharmacokinetics.
SUBSTANCE ABUSE IN PREGNANCY Aidan Foy Director, Alcohol and Drug Services, Newcastle Mater Misericordiae Hospital Introduction Substances used in pregnancy can interfere with the success of the pregnancy
More informationSubstance-Exposed Newborn
Substance-Exposed Newborn Definition: Substance-exposed newborn as a maltreatment occurs when a child is exposed to a controlled substance or alcohol prenatally. Exposure to a controlled substance or alcohol
More informationEffective Strategies for Addressing the Needs of Substance Exposed Newborns & their Families Dixie L. Morgese, BA, CAP, ICADC.
Effective Strategies for Addressing the Needs of Substance Exposed Newborns & their Families Dixie L. Morgese, BA, CAP, ICADC Key Issues Significant increase in number of pregnant women addicted to prescription
More informationNon-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2014 Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS) Michael
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationAbigail Plawman, MD. Addiction Medicine Fellowship Director MultiCare East Pierce Family Medicine.
Abigail Plawman, MD Addiction Medicine Fellowship Director MultiCare East Pierce Family Medicine plawmab@multicare.org COI statement No conflicts of interest to disclose Addiction (ASAM definition) Addiction
More informationMaternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health
Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health Columbus, Ohio Assignment Description The rapid advance of the opiate crisis has had far
More informationSAFE PRESCRIBING: RULES AND REGULATIONS. Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017
SAFE PRESCRIBING: RULES AND REGULATIONS Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017 DISCLOSURES I have no financial disclosures. OBJECTIVES Discuss the significance of the opiate
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationSubstance-Exposed Newborns
Substance-Exposed Newborns State of Oklahoma 2017 Substance-Exposed Newborns State of Oklahoma 2017 Legal Background Oklahoma statute, Title 63, 1-550.3, states, "The Department of Human Services shall
More informationSmoking Cessation in Pregnancy. Jessica Reader, MD, MPH Family Medicine Obstetrics Fellow June 1st, 2018
Smoking Cessation in Pregnancy Jessica Reader, MD, MPH Family Medicine Obstetrics Fellow June 1st, 2018 Tobacco Cessation in Pregnancy: Objective 1. Overview of the negative effects of tobacco abuse in
More informationIntroducing the Snuggle ME Recommendations: Care of Pregnant Women with Perinatal Substance Use with a Focus on Pain Management
Maine Quality Counts presents Provider Lunch & Learn: Pain Management Series Introducing the Snuggle ME Recommendations: Care of Pregnant Women with Perinatal Substance Use with a Focus on Pain Management
More informationMEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution
MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution IMPORTANT: Keep morphine sulfate oral solution in a safe place away from children. Accidental use by a child is a medical emergency
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral
More information